Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 3 4Phase NA 2Phase 1/2 2Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Other solid neoplasm 4Gastrointestinal 4Head & Neck 2Gynecologic 2Genitourinary 2Sarcoma 1Endocrine 1Dermatologic 1

Conditions

Wilms Tumor 1Urinary Bladder Neoplasms 1Mesothelioma, Malignant 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Platinum × Genitourinary × Clear all
NCT05765084 2026-06-05

Immuno-MESODEC

University Hospital, Antwerp

Phase 1/2 Recruiting
15 enrolled
GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Wilms Tumor

NCT01938573 2017-10-20

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

University of Washington

Phase 1/2 Completed
21 enrolled 4 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡